1.Evaluation of the relationship between lactacidemia and postoperative complications after surgery for peritoneal carcinomatosis
Marta Soriano HERVÁS ; Rosa JÁTIVA-PORCAR ; Daniel ROBLES-HERNÁNDEZ ; Anna Serra RUBERT ; Blanca SEGARRA ; Cristina OLIVA ; Javier ESCRIG ; José Antonio LLUECA
Korean Journal of Anesthesiology 2021;74(1):45-52
Background:
Cytoreductive surgery was developed as a treatment for peritoneal carcinomatosis. However, this surgery is associated with important complications. The present study aimed to assess the relationship between lactacidemia and the rate of associated complications during the immediate postoperative period in the intensive care unit (ICU) in patients undergoing cytoreductive surgery.
Methods:
This was a retrospective observational study. A total of 57 patients underwent cytoreductive surgery. All patients were admitted to the ICU immediately after the surgery. Data on lactic acid levels at the time of admission and discharge from the ICU were collected. Postsurgical complications that occurred during the ICU stay were recorded according to failure-to-rescue analysis and their severity stratified according to the Clavien-Dindo classification.
Results:
The lactic acid levels at admission to the ICU were significantly higher in patients who developed complications, with an almost tripled unadjusted relative risk (2.9, 95% CI: 1.6, 5.3), than in those who did not develop complications for the lactacidemia threshold established in the cumulative sum curve graphs. After adjustment for confounding effects, the relative risk became even higher (3.1, 95% CI: 1.8, 3.6). Lactic acid levels were still significantly higher in this group at the time of discharge from the ICU.
Conclusions
Serum lactate level is a risk factor for postoperative complications in patients undergoing cytoreductive surgery for peritoneal carcinomatosis. This study suggests that the risk of developing severe complications almost triples with a lactic acid level of 2.5 mmol/L or higher at the time of admission in the ICU.
2.Executive summary of the 2020 Clinical practice guidelines for the management of Dyslipidemia in the Philippines
Lourdes Ella Gonzalez-Santos ; Raymond Oliva ; Cecilia Jimeno ; Eddieson Gonzales ; Maria Margarita Balabagno ; Deborah Ona ; Jude Erric Cinco ; Agnes Baston ; Imelda Caole-Ang ; Mia Fojas ; Ruzenette Felicitas Hernandez ; Ma. Cristina Macrohon-Valdez ; Maria Theresa Rosqueta ; Felix Eduardo Punzalan ; Elmer Jasper Llanes
Journal of the ASEAN Federation of Endocrine Societies 2021;36(1):5-11
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually lower his risk for cardiovascular disease.
Dyslipidemias
;
Hyperlipoproteinemia Type II
;
Diabetes Mellitus